

Research Article

Antimycotic activity and in-silico validation of bioactive compounds of *Roccella montagnei* Bél. against clinically isolated onychomycosis fungus *Trichophyton mentagrophytes* (C.P. Robin) Sabour

Monalisha GIRI¹ , Sagarika PARIDA^{1,*} 

¹ Centurion University of Technology and Management, School of Applied Sciences, Department of Botany, Bhubaneswar, 752050 Odisha, India

ARTICLE INFO

Article history

Received: 19 May 2024

Revised: 09 September 2024

Accepted: 01 November 2024

Key words:

Antifungal activity,
Dermatophytosis, in-silico,
Trichophyton mentagrophytes

ABSTRACT

Dermatophytes are the most common slow growing contagious agents of cutaneous mycosis and persist as a significant public health issues despite of the availability of a number of antifungal medications. *Trichophyton mentagrophytes* (C.P. Robin) Sabour. is one of the fungal species which influences the dermatophytic diseases. A wide range of clinical dermatophytosis could infect scalp, face, hand, fingernails, toenails, feet, and also produce jock itch and ring worm of the body. Generally, terbinafine, is used to treat dermatophytosis induced by *Trichophyton* species. In most of the cases, synthetic anti-mycotic drugs fail over time resulting in development of resistant strains. Sustainable use of herbal sources has been recognised as novel therapeutic drugs to treat dermatophytic disorders. However, few reports are available on antimycotic activity of lichen species. Therefore, in this study, lichen species such as *Roccella montagnei* Bél was collected from prime locality of Bhubaneswar, Odisha. Antifungal potency of ethanol and methanol extractives of *R. montagnei* was screened by disc diffusion method against the clinical isolates of *T. Mentagrophytes* and standard deviation and error was calculated. The overall study resulted with a positive output and validated through in-silico database. Hence the entire study is based on biomedical evaluation and sustainable use of natural plant supplements for the benefit of human society.

Cite this article as: Giri M, Parida S. Antimycotic activity and in-silico validation of bioactive compounds of *Roccella montagnei* Bél. against clinically isolated onychomycosis fungus *Trichophyton mentagrophytes* (C.P. Robin) Sabour, USA. Environ Res Tec 2025;8(3)564-570.

INTRODUCTION

Dermatophytosis is the epidermal infection of living organisms with direct or indirect contact with harmful microorganisms. It is very common and harmful, to all categories of life. With time, these ignored infections affect internal body parts in immunocompromised patients [1]. The rate of dermatic treatment by synthetic pharmaceuticals is higher than by natural medicinal sources, although it is time-consuming and bears harmful side effects with long-term use. Some well-known derivatives, such as luliconazole, terbinafine, and ketoconazole, are becoming resistant to mutant

variants [2, 3]. Hence, the aim here is to localize the sustainable use of lichen species in dermatophytic infections as an effective source without any side effects [4]. In general, lichens are well known for monitoring pollution; here, the involvement of a fruticose lichen species, *Roccella montagnei* Bél [5]. is focused on treating clinically isolated onychomycosis fungus *Trichophyton mentagrophytes* (C.P. Robin) Sabour [6]. The antimicrobial activity confirmed the presence of some potential phytoconstituents in both methanolic and ethanolic extracts of *R. Montagnei*. *In silico* docking was also performed by using PubChem and Uniprot, to relate the experimental work [7].

*Corresponding author.

*E-mail address: sagarika.parida@cutm.ac.in



MATERIALS AND METHODS

Species Collection

In this study, the lichen species was collected from the shoot of *Roystonea regia* (Kunth) O. F. Cook, and identified as *Roccella montagnei* B  l. accession no. 52479 by Komal Kumar Ingle, National Botanical Research Institute (CSIR-NBRI), Lucknow, India. However, we have collected the organism *T. mentagrophytes* from KIIMS Hospital, Bhubaneswar, Odisha. A voucher specimen was deposited at Dept. of Botany, CUTM, Bhubaneswar.

Plant Sample Extraction

Exactly 100 grams of the unrefined lichen powder was extracted with methanol and ethanol (4 times 100 ml each) separately on a flask shaker for 24 to 48 hours, filtered, and concentrated on a rotary evaporator to extract the crude compounds.

Phytochemical Evaluation

Prilimnary phytochemical analyses was done for both methanolic and ethanolic extracts to detect the presence of different class of compounds such as alkaloids, saponins, carbohydrates, steroids, terpenoids, lipids, tannins, phytosterols and flavonoids [8].

Determination of in-vitro Antimicrobial Activity

The methanolic and ethanolic extract was considered for in-vitro antimicrobial assay against *T. mentagrophytes* to observe the effectiveness of *R. montagnei* for the cure of dermatophytosis. Sterilised discs (Himedia, SD067-1VL, 6mm sterile Susceptibility test disc) were dipped in 10 microliter of each extracts separately and allowed to dry for evaluation of antifungal activities by disc diffusion methods in separate petri plates containing standardized media combined with Sabouraud's dextrose agar (SDA) and Potato Dextrose agar (PDA) in 2:1 ratio. As the fungus was unable to grow in the existing media, therefore, standardisation of media was done for the growth of the clinical isolates in *in-vitro* condition. To measure the effectiveness, respective organic solvents are taken as negative control and the usual drug terbinafine was taken as a positive control. The plates were observed up to 5 to 8 days at 34-37   C inside a culture incubator and after one week, the zone of inhibition was measured by using zonic scale. The performed in-vitro work was verified through in-silico validation.

In-Silico Validation

Retrieval of phytoconstituents

In this study, 26 phyto-constituents of *R. montagnei* were selected by searching their information in various published literature [9, 10,11,12]. The physio-chemical record of these bioactive compounds was obtained through the database PubChem [13] in structure data format (SDF). Employing the BIOVIA Discovery Studio 4.5 Visualizer, the 3D struc-

tures were transformed to PDB format [14].

Lipinski rule of five

Lipinski's Rule of Five [15], is the necessary requirement to choose a potential drug candidate to find out an orally active medicine. The drug molecule has to adhere the specifications of parameters like molecular mass should be <=500 Dalton, logP value must be <=5, the no. of H- bond donor should be <=5, the no. of H- bond acceptors should be <=10, and molar refractivity value must be within 40-130. A molecule fails to qualify as a drug if its conditions are violated. TargetNet web server [16] employed to conjecture Lipinski's Rule of Five.

Validation of toxicity

The phyto-compounds were classified implementing Lipinski's Rule of Five. Potential compounds were vetted with the mcule database [17] to check the toxicity results of the compounds for their drug-likeness properties.

The protein sequence and structural information, of target genes of dermatophytosis viz., CHI3L2, MEP3 and DPPV are retrived from the UniProt database [18]. All the experimental structures of the target proteins of dermatophytosis caused by *T. mentagrophytes* are accessed through the Protein Data Bank (PDB) database [14]. Chain A of each structure chosen for analysis.

Specific target proteins are retrived using Uniprot tools [18], and three phyto-compounds; orcinol, 4-hydroxy benzoic acid, and divarinol, were marked efficient for in-silico drug docking among 26 compounds after considering remarkable parameters with the help of PubChem database [13].

RESULTS AND DISCUSSIONS

The antimicrobial activity of both methanolic and ethanolic extracts of *R. montagnei* shows effective results against *T. mentagrophytes* with an identified zone of inhibition. Standard deviation of three observations was depicted in Table 1. Standard error graph was plotted and shown in Figure 1.

Table 1. Antifungal activity of lichen extracts against *T. Menta-griphytes* compared with +ve and -ve controls

Solvents	*Zone of Inhibition (mm)
Methanol	13.67 �� 0.89
Ethanol	11�� 0.58
Terbinafine	3.33�� 0.33
Control	0




Figure 1. Zone of inhibition of lichen extracts against *T. Montagrophytes*

Maximum zone of inhibition was recorded as 13.67 ± 0.89 mm for methanolic extract followed by ethanolic extract with 11.0 ± 0.58 mm. Terbinafine showed minimum ZoI of 3.33 ± 0.33 mm, suggesting that the methanolic extract is effective than ethanolic extract and Terbinafine (Figure 2).

Preliminary phytochemical screening shows the presence of six class of phytochemicals in methanol and seven class of phytochemicals in ethanol extracts respectively from the extracts of *R. montagnei*, which validates the possible positive effect of antifungal results (Table 2).




Figure 2. Zone of inhibition of lichen extracts against *T. Montagrophytes* by disc diffusion method

Twenty-six phytochemicals have been retrieved from *R. Montagnei* from the reported literature, out of which only three follow Lipinsky's rule of five and are non-toxic in nature. The targeted three proteins such as chitinase-3-like protein 2, extracellular metalloproteinase 3 (Fungalsin), and dipeptidyl-peptidase 5 (alpha-keratin) are responsible for dermatophytic infections [10, 11]. The details of proteins available in Table 3 and Protein Data Base (PDB) ID taken for one protein, 4P8V, and the two are modeled using the Swiss Modeler tool.

Phyto-constituents from *R. montagnei*

Twenty-six phyto-constituents from the thallus of *R. montagnei* has been selected for this study and information was depicted in Table 3.

Selection of Non-toxic Phyto-constituents Following Lipinski Rule of Five Having Drug Likeliness Properties

TargetNet's web server was used to apply the Lipinski rule of five, which eliminated five compounds out of 26 retrieved phytoconstituents. Out of the 21 phytoconstituents, only three compounds fulfilling Lipinski's rule of five and are found non-toxic in nature with drug-likeliness properties (Table 4).

Table 2. Phytochemical screening of methanolic and ethanolic extracts of *R. montagnei*

Test	Methanol Extract	Ethanol Extract
Alkaloids	+++	++
Saponins	-	-
Carbohydrates	-	++
Steroids	+++	+++
Terpenoids	+	+++
Lipids	-	-
Tannin	+++	+++
Phytosterols	+	+++
Flavonoids	+++	+++

Table 3. Retrieved phytoconstituents of *R. montagnei*

Sl. No.	Chemical Name	Chemical formula	PubChem ID
1	Methyl- γ -Orsellinate	C ₉ H ₁₀ O ₄	76658
2	Roccellatol	C ₁₂ H ₁₆ O ₇	139591667
3	Ergosta-5, 7, 22-triene-3 β -ol	C ₂₈ H ₄₄ O	21139765
4	Ergosta- 7, 22-diene-3, 5,6-triol	C ₂₈ H ₄₆ O ₃	10181133
5	Ethyl 2,4-dihydroxy-6-methyl-3-(oxolan-2-yl)benzoate	C ₁₄ H ₁₈ O ₅	142736239
6	Erythrin	C ₂₀ H ₂₂ O ₁₀	72946996
7	Lecanoric acid	C ₁₆ H ₁₄ O ₇	99613
8	Rocellic acid	C ₁₇ H ₃₂ O ₄	11449446
9	Orcinol	C ₇ H ₈ O ₂	10436
10	Erythritol	C ₄ H ₁₀ O ₄	222285
11	Beta sitosterol	C ₂₉ H ₅₀ O	222284
12	Gallic acid	C ₇ H ₆ O ₅	370
13	Syringic acid	C ₉ H ₁₀ O ₅	10742
14	P-coumaric acid	C ₉ H ₈ O ₃	637542
15	Caffeic acid	C ₉ H ₈ O ₄	689043
16	Ferulic acid	C ₁₀ H ₁₀ O ₄	445858
17	Chlorogenic acid	C ₁₆ H ₁₈ O ₉	1794427
18	4-hydroxy benzoic acid	C ₇ H ₆ O ₃	135
19	Ethyl divaricatinatate	C ₁₃ H ₁₈ O ₄	179627
20	Divarinol	C ₉ H ₁₂ O ₂	3083600
21	Atranol	C ₈ H ₈ O ₃	458186
22	Ethyl haematommate	C ₁₁ H ₁₂ O ₅	3940691
23	Ethyl orsellinate	C ₁₀ H ₁₂ O ₄	75653
24	Sekikaic acid	C ₂₂ H ₂₆ O ₈	12315460
25	Ar-Turmerone	C ₁₅ H ₂₀ O	160512
26	Lichenxanthone	C ₁₆ H ₁₄ O ₅	5358904

Table 4. Lipinski rule of five analyses of the phytoconstituents of *R. montagnei*

Sl. No.	Chemical Name	Chemical formula	PubChem ID
1	Methyl- γ -Orsellinate	100.0%	Toxic
2	Roccellatol	100.0%	Toxic
3	Ethyl 2,4-dihydroxy-6-methyl-3-(oxolan-2-yl)benzoate	100.0%	Toxic
4	Lecanoric acid	100.0%	Toxic
5	Rocellic acid	100.0%	Toxic
6	Orcinol	100.0%	Non-toxic
7	Erythritol	100.0%	Toxic
8	Gallic acid	100.0%	Toxic
9	Syringic acid	100.0%	Toxic
10	P-coumaric acid	100.0%	Toxic
11	Caffeic acid	100.0%	Toxic
12	Ferulic acid	100.0%	Toxic
13	4-hydroxy benzoic acid	100.0%	Non-toxic
14	Ethyl divaricatinatate	100.0%	Toxic
15	Divarinol	100.0%	Non-toxic
16	Atranol	100.0%	Toxic
17	Ethyl haematommate	100.0%	Toxic
18	Ethyl orsellinate	100.0%	Toxic
19	Sekikaic acid	100.0%	Toxic
20	Ar-Turmerone	100.0%	Toxic
21	Lichenxanthone	100.0%	Toxic

Molecular Docking

For dermatophytosis caused by *T. mentagrophytes*, three proteins viz., Chitinase-3-like protein 2 (CHI3L2), Extracellular metalloproteinase 3 (Fungalysin) (MEP3) and Dipeptidyl-peptidase 5 (alpha-keratin) (DPPV) were selected (Table 5) from the reported literature for molecular docking using

CB DOCK 2.

The selected 3 phytochemicals were docked against the 3 selected protein targets by using CB DOCK 2, where divarinol scored the highest binding affinities of -6.3 kcal/mol, -6.0 kcal/mol, and -6.2 kcal/mol (Table 6, Figure 3).

Table 5. Selected target proteins of *T. mentagrophytes*

Entry ID (Uniport)	Protein Name	Gene Name	Aminoacid Length
Q15782	Chitinase-3-like protein 2	CHI3L2	390 4P8V (1.64)
Q6WIH8	Extracellular metalloproteinase 3 (Fungalysin)	MEP3	633 modelling
Q9UW98	Dipeptidyl-peptidase 5 (alpha-keratin)	DPPV	726 modelling

Table 6. Molecular docking study of selective bioactive compounds from *R. montagnei*

Protein	Docking score (ΔG , kcal/Mol)		
	Reported compound		
	Orcinol	4-hydroxy benzoic acid	Divarinol
Chitinase-3-like protein 2	-5.6	-5.0	-6.3
Extracellular metalloproteinase3 (fungalysin)	-5.6	-5.9	-6.0
Dipeptidyl-peptidase5 (alpha-keratin)	-5.2	-5.8	-6.2




Figure 3. 3D Interaction of target proteins with phytocompounds [* (a) chitinase protein-divarinol; (b) fungalsin-divarinol; (c) alpha-keratin-divarinol]

Lichens are rarely used drug derivatives in natural medicinal system, although they are so efficient as nutritional sources for mankind. The presence of proficient phyto-constituents reported from *R. montagnei*, are capable of treating dermatophytosis caused by *T. mentagrophytes*. This study revealed that the ethanolic and methanolic extracts of *R. montagnei* showed in vitro antifungal activity against onychomycosis caused by *T. mentagrophytes* and inhibit the growth of pathogen in a shorter period of time. Disk diffusion technique is considered in this study because it is one of the much simpler experiments for antifungal susceptibility test for dermatophytes and also easy to perform in the regular clinical practices as the broth dilution method [19]. Ethanolic extract shows more active compounds rather than the methanolic extract. In-silico docking of three refined phytocompounds from *R. montagnei* against three target proteins also showed effective results but amongst these three compounds divarinol is proved to be a potent phyto-constituent which scored with the highest binding affinities of -6.3 kcal/mol, -6.0 kcal/mol, and -6.2 kcal/mol and further research can be carried out to isolate this compound as a source for novel drug discovery. An investigation has [20] reported that methanol extracts of lichen species *Proto usnea poeppigii* inhibits a few fungal pathogens including *T. mentagrophytes* because of the presence of different metabolites such as usnic acid, isodivaricatic acid and divaricatinic acid which shows that lichen species can be a source for dermatophytic pathogens. This study could be used in discovering effective drugs against *T. mentagrophytes* [21].

Disk diffusion technique is considered in this study because it is one of the much simpler experiments for antifungal susceptibility test for dermatophytes and also easy to perform in the regular clinical practices as the broth dilution method.

CONCLUSION

Ethanolic and methanolic extract of *R. montagnei* showed inhibiting zones against *T. mentagrophytes*. In-silico docking also revealed the antidermatophytic effect of three phytoconstituents such as orcinol, 4-hydroxy benzoic acid and diva-

rinol. Out of these three, divarinol is found to be more effective with highest binding affinities with the selected three proteins. The overall work represents that *R. montagnei* can play a vital role as a source of natural medicines against *T. mentagrophytes*.

DATA AVAILABILITY STATEMENT

The authors confirm that the data that supports the findings of this study are available within the article. Raw data that support the finding of this study are available from the corresponding author, upon reasonable request.

CONFLICT OF INTEREST

The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

USE OF AI FOR WRITING ASSISTANCE

Not declared.

ETHICS

There are no ethical issues with the publication of this manuscript.

REFERENCES

1. J. Intra, C. Sarto, S. Mazzola, C. Fania, N. Tiberti, P. Brambilla, "In vitro activity of antifungal drugs against *Trichophyton rubrum* and *Trichophyton mentagrophytes* spp. by E-test method and non-supplemented Mueller-Hinton agar plates," *Mycopathologia*, Vol.184, pp. 517-523, 2019.
2. J. Roana, N. Mandras, D. Scalas, P. Campagna, V. Tullio, "Antifungal activity of *Melaleuca alternifolia*

- essential oil (TTO) and its synergy with itraconazole or ketoconazole against *Trichophyton rubrum*," *Molecules*, Vol. 26(2), pp. 461, 2021.
3. T. Mishra, S. Shukla, S. Meena, R. Singh, M. Pal, D. K. Upreti, D. Datta, "Isolation and identification of cytotoxic compounds from a fruticose lichen *Roccella montagnei*, and its in silico docking study against CDK-10," *Revista Brasileira de Farmacognosia*, pp. 724-728, 2017.
4. S. Dubale, D. Kebebe, A. Zeynudin, N. Abdissa, S. Suleman, "Phytochemical screening and antimicrobial activity evaluation of selected medicinal plants in Ethiopia," *Journal of Experimental Pharmacology*, pp. 51-62, 2023.
5. *Roccella montagnei* Bél. Index Fungorum last access 08.08.2024
6. *Trichophyton mentagrophytes* (C.P. Robin) Sabour. Index Fungorum last access 08.08.2024
7. S. Z. Khader, S. S. Ahmed, T. Arunachalam, S. Nayaka, S. K. Balasubramanian, S. T. SyedAmeen, P. Ponnusamy, "Radical scavenging potential, anti-inflammatory and antiarthritic activity of isolated isomer Methyl- γ -Orsellinate and roccellatol from *Roccella montagnei* Bel," *Bulletin of Faculty of Pharmacy, Cairo University*, Vol. 56(1), pp. 39-45, 2018.
8. U.V. Mallavadhani, A.V. Sudhakar, "Roccellatol, a new β -orcinol based metabolite from the lichen *Roccella montagnei*," *Natural Product Research*, Vol. 32(3), pp. 268-274, 2018.
9. V. B. Tatipamula, G. S. Vedula, A. V. Sastry, "Chemical and pharmacological evaluation of manglicolous lichen *Roccella montagnei* Bel em. DD Awasthi," *Future Journal of Pharmaceutical Sciences*, Vol. 5 pp. 1-9, 2019.
10. N. S. Vsdna, M. Muniappan, I. Kannan, S. Viswanathan, "Phytochemical analysis and docking study of compounds present in a polyherbal preparation used in the treatment of dermatophytosis," *Current Medical Mycology*, Vol. 3(4), pp. 6, 2017.
11. N. Hassan, M. Singh, S. Sulaiman, P. Jain, K. Sharma, S. Nandy, M. Dudeja, A. Ali, Z. Iqbal, "Molecular docking-guided ungual drug-delivery design for amelioration of onychomycosis," *ACS Omega*, Vol. 4(5), pp. 9583-9592, 2019.
12. P. Dixit, A. Maurya, T. Mishra, D.K. Upreti, and M. Pal, "Evaluation of Phytochemical Constituents and Antioxidant activity of the *Roccella montagnei*," *Cryptogam Biodiversity and Assessment*, vol. 2(1), pp. 14-18, 2017.
13. S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte and S.H. Bryant, "PubChem substance and compound databases," *Nucleic Acids Research*, 44(D1), D1202-D1213, 2016.
14. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig and P.E. Bourne, "The protein data bank," *Nucleic Acids Research*, 28(1), pp. 235-242, 2000.
15. X. Chen, H. Li, L. Tian, Q. Li, J. Luo and Y. Zhang, "Analysis of the physicochemical properties of acaricides based on Lipinski's rule of five," *Journal of Computational Biology*, vol. 27(9), pp. 1397-1406, 2020.
16. Z.J. Yao, J. Dong, Y.J. Che, M.F. Zhu, M. Wen, N.N. Wang, and D.S. Cao, "TargetNet: a web service for predicting potential drug-target interaction profiling via multi-target SAR models," *Journal of Computer-aided Molecular Design*, vol. 30, pp. 413-424, 2016.
17. R. Kiss, M. Sandor and F.A. Szalai, <http://McuLe.com: a public web service> for drug discovery, *Journal of Cheminformatics*, 4(Suppl 1), P17, 2012.
18. UniProt Consortium, T. "UniProt: the universal protein knowledgebase," *Nucleic Acids Research*, vol. 46(5), pp. 2699-2699, 2018.
19. A.B. Macura, "In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods," *International Journal of Dermatology*, vol. 32(7), pp. 533-536, 1993.
20. H.F. Chambers, "Community-associated MRSA—resistance and virulence converge," *New England Journal of Medicine*, vol. 352(14), pp. 1485-1487, 2005.
21. M. Giri and S. Parida, "Phytochemical inhibitors from *Leucas aspera* against the target proteins induced by *Trichophyton mentagrophytes* using computational techniques," *Journal of Basic Microbiology*, e202400112. 2024.